Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422
{{output}}
Background: Immunotherapy targeting pathological α-synuclein (α-syn) species is a promising strategy for slowing disease progression in neurodegenerative synucleinopathies, including Parkinson's disease (PD). ... ...